Journal September 26, 2026 5 min read

What markers track proteostasis?

Proteostasis is tracked by markers of ubiquitin-proteasome and autophagy-lysosomal flux, chaperone levels, mitochondrial quality control, and stress-response transcription factors. This page reviews the evidence for each

peptides-pro Editorial

Proteostasis, or protein homeostasis, refers to the integrated cellular networks that maintain the proteome: protein synthesis, folding, trafficking, and degradation. The term encompasses the ubiquitin-proteasome system (UPS), autophagy-lysosomal pathways (ALP), chaperone networks, and mitochondrial quality control (mtQC). No single molecular identifier defines proteostasis; instead, it is assessed through a panel of markers reflecting the activity and capacity of these pathways. Commonly measured markers include ubiquitinated protein conjugates, LC3-II (a lipidated form of microtubule-associated protein 1A/1B-light chain 3), p62/SQSTM1, heat shock proteins (e.g., HSP70, HSP90), and components of the mitochondrial unfolded protein response (UPRmt). These markers are proteins or protein modifications, not small molecules, and their levels are typically quantified by immunoblotting, immunofluorescence, or mass spectrometry.

The work centres on the ubiquitin-proteasome and autophagy-lysosomal systems, with crosstalk to mitochondrial quality control and stress-responsive transcription factors such as CHOP and NF-κB.

Research Studies

Astrocytic proteostasis markers in Parkinson's disease models

In a system-level model of Parkinson's disease (PD), pathological α-synuclein was reported to trigger astrocytic failure, including impaired proteostasis via ubiquitin-proteasome and autophagy-lysosomal pathways [1]. The review synthesizes evidence that astrocyte dysfunction, or astrocytopathy, is a central driver of pathogenesis, with markers of proteostatic impairment observed in astrocytes. This work is a review of primarily preclinical and human post-mortem data; it does not report a specific marker panel validated for clinical use.

NMNAT-1 and NAD+ homeostasis in neuroprotection and aging

Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT-1) catalyses the final step in NAD+ biosynthesis and is the major nuclear isoform of the mammalian NMNAT family [4]. Age-associated NAD+ decline has been implicated in brain aging and neurodegenerative disorders, but the causal node and limiting compartment differ across tissues and disease states [4]. Direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited axonal degeneration [4]. Markers of NAD+ homeostasis, such as NAD+ levels and NMNAT-1 expression, are therefore studied as indicators of proteostatic and metabolic stress, though their utility as proteostasis-specific markers remains context-dependent.

CCT/TRiC chaperonin in glioblastoma therapy-induced senescence

Glioblastoma multiforme (GBM) is chaperone dependent, relying on proteostasis networks for growth, invasion, and treatment resistance [5]. The eukaryotic chaperonin CCT/TRiC is a key component of this network. In GBM, standard therapies drive many cells into therapy-induced senescence (TIS), marked by permanent proliferation arrest, high metabolic activity, and the senescence-associated secretory phenotype (SASP) [5]. CCT/TRiC levels and activity are studied as markers of proteostatic adaptation in this context, though the evidence is largely from cell lines and animal models.

Mitochondrial quality control markers in DNA damage-induced senescence

In mouse embryonic fibroblasts (MEFs), deficiency in the mitochondrial protease HtrA2 (proteostasis), the transcription factor Chop (integrated stress response; ISR), or the mitophagy regulator Pink1 modulated senescence induction by genotoxic challenge [6]. This study used three mechanistically distinct DNA-damaging agents and measured markers of mtQC and stress signalling. The findings are animal-cell-based (MEFs) and may not translate directly to human physiology.

Circadian clock markers and proteostasis in Alzheimer's disease

In Alzheimer's disease (AD), disruptions in circadian rhythms and sleep-wake regulation have been associated with altered proteostasis [7]. Mechanistic studies suggest interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity, and proteostasis [7]. Disruptions in circadian-regulated molecular pathways, including BMAL1-SIRT1 and NF-κB-NLRP3, are studied as markers linking circadian dysfunction to proteostatic failure [7]. This is a narrative review; the evidence is largely from preclinical models and human observational studies.

Plant cell protectors under salinity stress

In plants, salinity stress induces osmotic imbalance, ionic toxicity, and oxidative stress, leading to disruptions in photosynthesis, metabolism, and development [8]. Structural protectors such as the cell wall, plasma membrane, vacuole, and peroxisome maintain cellular homeostasis under saline conditions [8]. While not directly analogous to mammalian proteostasis, these systems involve markers of protein damage and repair, such as reactive oxygen species (ROS) and chaperone-like proteins. This evidence is plant-specific and not applicable to human biology.

Autophagy markers in hypothalamic neurons

In the arcuate nucleus, autophagy exerts divergent metabolic effects in the two principal appetite-regulating neuron populations, POMC and AgRP neurons [9]. Markers such as LC3-II and p62 are used to assess autophagic flux in these neurons. This work is from animal models and is relevant to obesity research, not directly to human proteostasis monitoring.

Mitochondrial quality control in autoimmune diseases

In heterogeneous autoimmune diseases (AIDs), mitochondrial quality control (mtQC) is emerging as a mechanism and biomarker [11]. New evidence highlights mtQC pathways as potential windows for intervention, though the specific markers and their validity in human AIDs require further study [11]. This is a review of preclinical and early clinical data.

T-2 toxin effects on App/Tau homeostasis in neuroblastoma cells

In SH-SY5Y human neuroblastoma cells, low-dose T-2 toxin (6 nM) for 24 h disrupted Alzheimer's-relevant App/Tau homeostasis via circadian-p53-senescence crosstalk [12]. Markers included AD-relevant protein changes, transcriptomic, circadian, and senescence-related readouts [12]. This is an in vitro study; the findings may not reflect in vivo human biology.

If you are reading this for personal health reasons

The compounds and markers discussed here are sold for laboratory research only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.